<DOC>
	<DOCNO>NCT00405054</DOCNO>
	<brief_summary>This study evaluate MK0457 patient chronic myelogenous leukemia Philadelphia chromosome-positive acute lymphoblastic leukemia . Efficacy safety evaluate .</brief_summary>
	<brief_title>A Phase II Study MK0457 Patients With T315I Mutant CML Ph+All ( 0457-008 )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<criteria>This study evaluate MK0457 patient CML ( chronic myelogenous leukemia ) Ph+ALL ( Philadelphia chromosomepositive acute lymphoblastic leukemia ) Patients must adequate organ function Patients must document T315I mutation Patients within 3 month allogeneic bone marrow transplant fully recover previous antileukemia therapy Patients uncontrolled congestive heart failure Patients active uncontrolled infection active Hepatitis B C Patients know HIV positivity AIDS relate illness Patients currently active second malignancy , nonmelanoma skin cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>